Literature DB >> 19666848

Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production.

Jennifer M Kleinhenz1, Dean J Kleinhenz, Shaojin You, Jeffrey D Ritzenthaler, Jason M Hansen, David R Archer, Roy L Sutliff, C Michael Hart.   

Abstract

Vascular endothelial cells express the ligand-activated transcription factor, peroxisome proliferator-activated receptor-gamma (PPARgamma), which participates in the regulation of metabolism, cell proliferation, and inflammation. PPARgamma ligands attenuate, whereas the loss of function mutations in PPARgamma stimulate, endothelial dysfunction, suggesting that PPARgamma may regulate vascular endothelial nitric oxide production. To explore the role of endothelial PPARgamma in the regulation of vascular nitric oxide production in vivo, mice expressing Cre recombinase driven by an endothelial-specific promoter were crossed with mice carrying a floxed PPARgamma gene to produce endothelial PPARgamma null mice (ePPARgamma(-/-)). When compared with littermate controls, ePPARgamma(-/-) animals were hypertensive at baseline and demonstrated comparable increases in systolic blood pressure in response to angiotensin II infusion. When compared with those of control animals, aortic ring relaxation responses to acetylcholine were impaired, whereas relaxation responses to sodium nitroprusside were unaffected in ePPARgamma(-/-) mice. Similarly, intact aortic segments from ePPARgamma(-/-) mice released less nitric oxide than those from controls, whereas endothelial nitric oxide synthase expression was similar in control and ePPARgamma(-/-) aortas. Reduced nitric oxide production in ePPARgamma(-/-) aortas was associated with an increase in the parameters of oxidative stress in the blood and the activation of nuclear factor-kappaB in aortic homogenates. These findings demonstrate that endothelial PPARgamma regulates vascular nitric oxide production and that the disruption of endothelial PPARgamma contributes to endothelial dysfunction in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666848      PMCID: PMC2781385          DOI: 10.1152/ajpheart.00148.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  58 in total

Review 1.  Cre recombinase: the universal reagent for genome tailoring.

Authors:  A Nagy
Journal:  Genesis       Date:  2000-02       Impact factor: 2.487

2.  PPAR gamma is required for placental, cardiac, and adipose tissue development.

Authors:  Y Barak; M C Nelson; E S Ong; Y Z Jones; P Ruiz-Lozano; K R Chien; A Koder; R M Evans
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

3.  Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.

Authors:  A R Collins; W P Meehan; U Kintscher; S Jackson; S Wakino; G Noh; W Palinski; W A Hsueh; R E Law
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-03       Impact factor: 8.311

4.  Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

Authors:  Z Chen; S Ishibashi; S Perrey; T Gotoda; T Kitamine; Y Tamura; H Okazaki; N Yahagi; Y Iizuka; F Shionoiri; K Ohashi; K Harada; H Shimano; R Nagai; N Yamada
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-03       Impact factor: 8.311

5.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

6.  Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling.

Authors:  Hanke Mollnau; Maria Wendt; Katalin Szöcs; Bernard Lassègue; Eberhard Schulz; Mathias Oelze; Huige Li; Martin Bodenschatz; Michael August; Andrei L Kleschyov; Nikolaus Tsilimingas; Ulrich Walter; Ulrich Förstermann; Thomas Meinertz; Kathy Griendling; Thomas Münzel
Journal:  Circ Res       Date:  2002-03-08       Impact factor: 17.367

Review 7.  Mechanisms of the antioxidant effects of nitric oxide.

Authors:  D A Wink; K M Miranda; M G Espey; R M Pluta; S J Hewett; C Colton; M Vitek; M Feelisch; M B Grisham
Journal:  Antioxid Redox Signal       Date:  2001-04       Impact factor: 8.401

8.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

Authors:  A C Li; K K Brown; M J Silvestre; T M Willson; W Palinski; C K Glass
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

9.  Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

Authors:  R E Law; S Goetze; X P Xi; S Jackson; Y Kawano; L Demer; M C Fishbein; W P Meehan; W A Hsueh
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

10.  Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.

Authors:  T Takagi; T Akasaka; A Yamamuro; Y Honda; T Hozumi; S Morioka; K Yoshida
Journal:  J Am Coll Cardiol       Date:  2000-11-01       Impact factor: 24.094

View more
  47 in total

1.  Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse.

Authors:  Alana L Reed; Atsuko Tanaka; Dan Sorescu; Hong Liu; Euy-Myoung Jeong; Megan Sturdy; Erik R Walp; Samuel C Dudley; Roy L Sutliff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-01       Impact factor: 4.733

2.  PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B.

Authors:  Xianghuai Lu; Tamara C Murphy; Mark S Nanes; C Michael Hart
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-07-09       Impact factor: 5.464

Review 3.  Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma.

Authors:  Pimonrat Ketsawatsomkron; Curt D Sigmund
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-03       Impact factor: 2.894

4.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

5.  Endothelin-1 decreases endothelial PPARγ signaling and impairs angiogenesis after chronic intrauterine pulmonary hypertension.

Authors:  David Wolf; Nancy Tseng; Gregory Seedorf; Gates Roe; Steven H Abman; Jason Gien
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-13       Impact factor: 5.464

Review 6.  PPARγ Regulation in Hypertension and Metabolic Syndrome.

Authors:  Madeliene Stump; Masashi Mukohda; Chunyan Hu; Curt D Sigmund
Journal:  Curr Hypertens Rep       Date:  2015-12       Impact factor: 5.369

Review 7.  Electrophilic nitro-fatty acids: anti-inflammatory mediators in the vascular compartment.

Authors:  Nicholas K H Khoo; Bruce A Freeman
Journal:  Curr Opin Pharmacol       Date:  2010-01-14       Impact factor: 5.547

8.  Hypoxia downregulates PPARγ via an ERK1/2-NF-κB-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells.

Authors:  Xianghuai Lu; Kaiser M Bijli; Allan Ramirez; Tamara C Murphy; Jennifer Kleinhenz; C M Hart
Journal:  Free Radic Biol Med       Date:  2013-05-15       Impact factor: 7.376

9.  Peroxisome Proliferator-Activated Receptor γ Regulates the V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1/microRNA-27a Axis to Reduce Endothelin-1 and Endothelial Dysfunction in the Sickle Cell Mouse Lung.

Authors:  Bum-Yong Kang; Kathy Park; Jennifer M Kleinhenz; Tamara C Murphy; Roy L Sutliff; David Archer; C Michael Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2017-01       Impact factor: 6.914

10.  PPARgamma Agonists: Blood Pressure and Edema.

Authors:  Bonnie L Blazer-Yost
Journal:  PPAR Res       Date:  2009-12-22       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.